These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 2267905

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide.
    Knauf H, Mutschler E.
    Cardiology; 1994; 84 Suppl 2():87-98. PubMed ID: 7954550
    [Abstract] [Full Text] [Related]

  • 3. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients.
    Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C.
    Hepatology; 1991 Aug; 14(2):231-6. PubMed ID: 1860680
    [Abstract] [Full Text] [Related]

  • 4. [Influence of non-sodium restricted diet with diuretics on plasma rennin, renal blood flow and in patients with cirrhotic ascites].
    Zhu YF, Gu XB, Zhu HY, Yang XJ, Wang D, Yu P.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Feb; 27(1):50-3. PubMed ID: 23855131
    [Abstract] [Full Text] [Related]

  • 5. An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide.
    Fuller RK, Khambatta PB, Gobezie GC.
    JAMA; 1977 Mar 07; 237(10):972-5. PubMed ID: 319263
    [Abstract] [Full Text] [Related]

  • 6. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
    Santos J, Planas R, Pardo A, Durández R, Cabré E, Morillas RM, Granada ML, Jiménez JA, Quintero E, Gassull MA.
    J Hepatol; 2003 Aug 07; 39(2):187-92. PubMed ID: 12873814
    [Abstract] [Full Text] [Related]

  • 7. Pathogenesis of ascites and renal salt retention in cirrhosis.
    Palmer BF.
    J Investig Med; 1999 May 07; 47(5):183-202. PubMed ID: 10361377
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Loop diuretic therapy in liver cirrhosis with ascites.
    Laffi G, La Villa G, Carloni V, Foschi M, Bartoletti L, Quartini M, Gentilini P.
    J Cardiovasc Pharmacol; 1993 May 07; 22 Suppl 3():S51-8. PubMed ID: 7506337
    [Abstract] [Full Text] [Related]

  • 11. Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis.
    Arroyo V, Ginès P, Planas R.
    Gastroenterol Clin North Am; 1992 Mar 07; 21(1):237-56. PubMed ID: 1568775
    [Abstract] [Full Text] [Related]

  • 12. [Reasons for diuretic therapy of cirrhotic ascites].
    Parlapiano C, Paoletti V.
    Minerva Med; 1985 Nov 10; 76(43):2043-6. PubMed ID: 3934593
    [Abstract] [Full Text] [Related]

  • 13. Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients.
    Ljubicić N, Kujundzić M, Banić M, Vrkljan M.
    Scand J Gastroenterol; 1998 Apr 10; 33(4):441-7. PubMed ID: 9605268
    [Abstract] [Full Text] [Related]

  • 14. Torasemide in the treatment of patients with cirrhosis and ascites.
    Gentilini P, Laffi G, La Villa G, Carloni V, Foschi M, Romanelli RG, Marra F.
    Cardiovasc Drugs Ther; 1993 Jan 10; 7 Suppl 1():81-5. PubMed ID: 8435382
    [Abstract] [Full Text] [Related]

  • 15. [Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
    Lenaerts A, Codden T, Henry JP, Van Cauter J, Meunier JC, Ligny G.
    Gastroenterol Clin Biol; 2001 Mar 10; 25(3):268-72. PubMed ID: 11395674
    [Abstract] [Full Text] [Related]

  • 16. Use of diuretics in the treatment of cirrhotic ascites.
    Boyer TD, Warnock DG.
    Gastroenterology; 1983 May 10; 84(5 Pt 1):1051-5. PubMed ID: 6832557
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacotherapy of ascites associated with cirrhosis.
    Ginès P, Arrovo V, Rodés J.
    Drugs; 1992 Mar 10; 43(3):316-32. PubMed ID: 1374317
    [Abstract] [Full Text] [Related]

  • 18. Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis.
    Radó JP, Sawinsky I, Juhos E.
    Int J Clin Pharmacol Biopharm; 1976 Oct 10; 14(3):163-7. PubMed ID: 1002353
    [Abstract] [Full Text] [Related]

  • 19. Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine.
    Sansoè G, Aragno M, Mastrocola R, Mengozzi G, Parola M.
    PLoS One; 2016 Oct 10; 11(7):e0158486. PubMed ID: 27384184
    [Abstract] [Full Text] [Related]

  • 20. Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites.
    Spahr L, Villeneuve JP, Tran HK, Pomier-Layrargues G.
    Hepatology; 2001 Jan 10; 33(1):28-31. PubMed ID: 11124817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.